These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 38642081

  • 1. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
    Delgado-Coka LA, Roa-Peña L, Babu S, Horowitz M, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Akalin A, Jiang W, Larson BK, Hendifar AE, Picozzi VJ, Choi M, Shroyer KR, Escobar-Hoyos LF.
    Am J Clin Pathol; 2024 Sep 03; 162(3):314-326. PubMed ID: 38642081
    [Abstract] [Full Text] [Related]

  • 2. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
    Pan CH, Otsuka Y, Sridharan B, Woo M, Leiton CV, Babu S, Torrente Gonçalves M, Kawalerski RR, K Bai JD, Chang DK, Biankin AV, Scampavia L, Spicer T, Escobar-Hoyos LF, Shroyer KR.
    Mol Oncol; 2020 Aug 03; 14(8):1800-1816. PubMed ID: 32533886
    [Abstract] [Full Text] [Related]

  • 3. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.
    Roa-Peña L, Leiton CV, Babu S, Pan CH, Vanner EA, Akalin A, Bandovic J, Moffitt RA, Shroyer KR, Escobar-Hoyos LF.
    Sci Rep; 2019 Aug 02; 9(1):11239. PubMed ID: 31375762
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Keratin 17 modulates the immune topography of pancreatic cancer.
    Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton CV, Hasan M, Babu S, Fassler D, Oentoro J, Bai JK, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos LF, Shroyer KR.
    J Transl Med; 2024 May 10; 22(1):443. PubMed ID: 38730319
    [Abstract] [Full Text] [Related]

  • 7. Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarcinoma and correlate with survival outcome.
    Chen Q, Chen Z, Zhang J, Cai Y, Wu S, He D, Cheng K, Gu X, Cai Y, Wang X, Li Y, Zhang M, Wu Z, Peng B.
    FASEB J; 2024 Aug 15; 38(15):e23867. PubMed ID: 39101950
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 15; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 10. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Hayashi A, Souzaki R, Tajiri T, Onimaru M, Manabe T, Ohtsuka T, Tanaka M.
    Int J Oncol; 2011 Mar 15; 38(3):629-41. PubMed ID: 21243324
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
    Bird NT, Elmasry M, Jones R, Psarelli E, Dodd J, Malik H, Greenhalf W, Kitteringham N, Ghaneh P, Neoptolemos JP, Palmer D.
    Br J Surg; 2017 Mar 15; 104(4):328-336. PubMed ID: 28199010
    [Abstract] [Full Text] [Related]

  • 12. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y, Ji B, Jiang CX, Chen ZM, Yao NH, Mukaida N, Huang H.
    Pathol Res Pract; 2019 Dec 15; 215(12):152650. PubMed ID: 31585811
    [Abstract] [Full Text] [Related]

  • 13. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A, Puleo F, Bachet JB, Ouazzani S, Calomme A, Demetter P, Verset G, Van Laethem JL, Maréchal R.
    Br J Cancer; 2016 Nov 08; 115(10):1245-1252. PubMed ID: 27755532
    [Abstract] [Full Text] [Related]

  • 14. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
    Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR.
    Ann Surg; 2018 Feb 08; 267(2):364-369. PubMed ID: 27893535
    [Abstract] [Full Text] [Related]

  • 15. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
    Striefler JK, Sinn M, Pelzer U, Jühling A, Wislocka L, Bahra M, Sinn BV, Denkert C, Dörken B, Oettle H, Riess H, Bläker H, Lohneis P.
    Pathol Res Pract; 2016 Aug 08; 212(8):726-34. PubMed ID: 27461834
    [Abstract] [Full Text] [Related]

  • 16. Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma.
    Shibayama T, Hayashi A, Toki M, Kitahama K, Ho YJ, Kato K, Yamada T, Kawamoto S, Kambayashi K, Ochiai K, Gondo K, Okano N, Melchor JP, Iacobuzio-Donahue CA, Sakamoto Y, Hisamatsu T, Shibahara J.
    Sci Rep; 2024 Jul 06; 14(1):15598. PubMed ID: 38971768
    [Abstract] [Full Text] [Related]

  • 17. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M, Gotoh K, Eguchi H, Kobayashi S, Iwagami Y, Tomimaru Y, Akita H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y.
    Ann Surg Oncol; 2020 Feb 06; 27(2):610-619. PubMed ID: 31605325
    [Abstract] [Full Text] [Related]

  • 18. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
    Kato A, Naiki-Ito A, Naitoh I, Hayashi K, Nakazawa T, Shimizu S, Nishi Y, Okumura F, Inoue T, Takada H, Kondo H, Yoshida M, Takahashi S, Joh T.
    Hum Pathol; 2018 Apr 06; 74():92-98. PubMed ID: 29339176
    [Abstract] [Full Text] [Related]

  • 19. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C, Bitzer M, Malek NP, Plentz RR.
    Scand J Gastroenterol; 2014 Dec 06; 49(12):1480-5. PubMed ID: 25390691
    [Abstract] [Full Text] [Related]

  • 20. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL.
    Gastroenterology; 2012 Sep 06; 143(3):664-674.e6. PubMed ID: 22705007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.